Corporate News

Cantel Medical Corp. (NYSE: CMN) will replace NATCO Group Inc. (NYSE: NTG) after the close of trading on a date to be announced. NATCO is being acquired by S&P 500 constituent Cameron International Corp. (NYSE: CAM) in a deal expected to be completed soon pending final approvals.

Calavo Growers Inc. (NASDAQ: CVGW) will replace Sterling Financial Corp. (NASDAQ: STSA) after the close of trading on Wednesday, November 18. Sterling Financial has a market capitalization below $35 million, ranking it 600th in the index.

Note: changes will be to the S&P SmallCap 600 Index.

Kinross (NYSE: KGC) announced today that it has entered into an agreement with Export Development Canada to have EDC guarantee a Letter of Credit Facility for up to $125 million. Letters of credit guaranteed under this new facility are expected to be available in respect of reclamation liabilities at Fort Knox, Round Mountain, and Kettle River-Buckhorn mine sites. The new facility will expire in November 2012.

The guarantee facility is in addition to the Company's recently amended $450 million revolving credit facility. "Together, these facilities enhance Kinross' credit availability as we contemplate our future funding requirements," said Thomas M. Boehlert, Executive Vice-President and Chief Financial Officer.

Endo Pharmaceuticals (NASDAQ: ENDP) announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

Endo Pharmaceuticals has agreed to make a one-time, $23 million payment for the exclusive license to these two patents for use in the field of prescription pain medicines and treatment. "We are pleased to add these patents to our IP inventory especially as they relate to Lidoderm," said Caroline Manogue, executive vice president and chief legal officer of Endo Pharmaceuticals.

Trubion Pharmaceuticals, Inc. (NASDAQ: TRBN) announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

The presentations will include additional positive data from 1) an ongoing Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), and 2) a preclinical study demonstrating the effect of Trubion's Tru-ADhanCe( technology in promoting enhanced natural killer cell mediated cytotoxicity against primary CLL cells. TRU-016 is Trubion's novel CD37-targeted therapy for the treatment of B-cell malignancies and is being developed in collaboration with Facet Biotech Corporation.

Presentation 3424: A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP(TM)) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity

Monday, Dec. 7, 2009, 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
Poster Board III-361

Conclusions: To date, TRU-016 is a well-tolerated treatment with minimal infusional toxicity and the maximum tolerated dose (MTD) has not been reached. One partial response (PR) and a median reduction of 83% in peripheral lymphocytosis have been observed. Encouraging reduction in lymph node/spleen size and improvement in normal hematopoietic function in patients with high-risk genomic CLL have been observed at low doses of CD37. The protocol has been amended to explore higher saturating doses of CD37. Future single-agent and combination studies of TRU-016 in CLL are warranted.

Presentation 1744: Glycovariant CD37 Small Modular Immunopharmaceutical (Tru-ADhanCe(TM) SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary CLL Cells

Saturday, Dec. 5, 2009, 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)
Poster Board I-766

Conclusions: Results of this study suggest that Tru-ADhanCe(TM) technology promotes enhanced natural killer cell mediated cytotoxicity against primary CLL cells and the potential use of Tru-ADhanCe versions of TRU-016 with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) function as an alternate for TRU-016 in B cell malignancies, including CLL therapy.

S&P has revised its outlook on Sirius XM (Nasdaq: SIRI) from Stable to Positive